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INTRODUCTION: Chordoid glioma is a rare low-grade brain tumor originating from the anterior wall of
the third ventricle.
CASE PRESENTATION: A 13-year-old female with progressive intermittent holocranial headaches and a
diagnosis of chordoid glioma underwent tumor resection in our neuro-oncology unit.
DISCUSSION: We review all 79 cases of chordoid glioma reported in the literature so far, focusing on the
diagnostic criteria, treatment options and prognosis.
CONCLUSION: Efﬁcient treatment of chordoid glioma depends upon radical surgical resection. Based on
the reviewed data, which showed high morbi-mortality rates for this kind of tumor, we recommend a
more conservative treatment approach.
© 2015 The Authors. Published by Elsevier Ltd. on behalf of Surgical Associates Ltd. This is an open
access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction
Chordoid glioma (CG) is a rare low-grade tumor that arises from
the anterior wall or roof of the third ventricle. It was ﬁrst described
in 1998 by Brat et al. [1]. In 2000, it was incorporated into the
World Health Organization (WHO) classiﬁcation as grade II [2].
Chordoid glioma affects women at a rate of 2:1, and most patients
are between 30 and 60 years of age [3].
This tumor was named chordoid glioma because of its distinc-
tive histologic appearance, reminiscent of chordoma, and its avid
staining with glial ﬁbrillary acidic protein (GFAP) in immunohisto-
chemical analyses [4]. After a cross-referenced PubMed search that
yielded 79 published cases, we present one illustrative case and
review the diagnostic criteria, treatment options and prognosis.
2. Case presentation
A 13-year-old girl presented with 2 weeks of progressive
intermittent holocranial headaches, with no speciﬁc behavioral
alterations. Magnetic resonance imaging (MRI) showed a well-
deﬁned lesion adjacent to the ﬂoor of the third ventricle, with
little surrounding edema. The initial diagnosis was intraventricular
meningioma, which was resected in 2003 at a regional hospital in
Sao Paulo, Brazil.
In 2011, a new resection was performed due to lesion regrowth.
The new histological diagnosis was gliosarcoma. An oncologist
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conducted 28 sessions of adjuvant radiotherapy (50, 4Gy). Post-
operatively, the patient evolved with diabetes insipidus (DI) and
hypothyroidism. A follow-up with serial MRI was conducted and
three months after this surgery, the patient began experiencing
convulsive seizures.
In 2012, tumor regrowth in the hypothalamic region was
detected via MRI. At this time, the patient presented with
behavioral alterations characterized by psychomotor impairment,
despite a Karnofsky score of 90 and an Eastern Cooperative Oncol-
ogy Group (ECOG) score of 1 (Fig. 1).
When the patient was then referred to our oncology unit, we
opted for a total transcortical resection guided by neuronavigation
(Fig. 2). Thematerial from the second surgerywas sent to adifferent
laboratory for a second histological diagnosis, along with material
from the third surgery (Fig. 3). The anatomo-pathological report
revealed a CG of the third ventricle. Postoperatively, the patient
had improved psychomotor function and mild mental confusion,
and maintained her previous Karnofsky and ECOG scores (90 and
1, respectively).
3. Discussion
3.1. Clinical presentation
Initial presentations of CG vary from asymptomatic to aggres-
sive, and most cases show slow and mild progression. Speciﬁc
symptoms are attributable to the speciﬁc tumor location and to
the involvement of adjacent structures responsible for possible
endocrine alterations, visual deﬁcits and behavioral alterations,
http://dx.doi.org/10.1016/j.ijscr.2015.01.027
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Fig. 1. Coronal, sagittal and axial T1 gadolinium-contrast and T2 axial images showing a tumor in the 3rd ventricle.
as well as symptoms secondary to an obstructive hydrocephalus
[4–6].
In the case reported herein, the patient initially presented with
a headache and as the tumor progressed, developed behavioral and
endocrine complications.
3.2. Differential diagnoses
Suprasellar masses (including pituitary macroadenomas, cran-
iopharyngiomas, meningiomas, metastases, optic and hypothala-
mic pilocytic astrocytomas) account for more than 75% of these
lesions. Tumors of the third ventricle constitute an uncommon
subset of suprasellar masses, and offer differential diagnostic
value, excluding meningiomas, craniopharyngioma, hypothalamic
gliomas, hypothalamic hamartoma, germ cell tumors, and others
[7,8].
Meningioma is among these differential diagnoses, which was
our patient’s initial diagnosis. Kobayashi et al [2] also reported
three caseswith initial diagnoses of ventricularmeningioma. These
neoplasms had histologic appearance of cords and clusters of
epithelioid cells within a mucinous background, along with a low-
grade lymphoplasmacytic inﬁltrate reminiscent of a chordoma or
chordoid meningioma. Unlike meningiomas, which are not glial in
origin, all CG stained avidly for the glial cell marker GFAP [2,9].
Fig. 2. Immediate Postoperative coronal, sagittal and axial T1 gadolinium-contrast images.
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Fig. 3. Photomicrographs of the tumor (original magniﬁcation x400). (A) Hematoxylin and Eosin stained slides show strands and ribbons of eosinophilic abundant cytoplasm
and epitheliod neoplastic cells on myxoid basophilic matrix. (B) Immunostained slide for glial-ﬁbrillary acid protein (GFAP) shows diffuse and strong expression in neoplastic
cells. (C) Immunostained slide for epithelial membrane antibody (EMA) shows diffuse and strong expression in neoplastic cells. (D) Immunostained slide for CD 34 shows
focal and strong expression in neoplastic cells.
3.3. Diagnostic imaging
CG appears hyperdense on computed tomography (CT) in 65%
of cases, and enhances homogeneously following contrast adminis-
tration in 68%. CG may be confused with other hyperdense lesions,
such as lymphoma, meningioma and aneurysms.
MRI is preferred for CG because it clearly depicts the hypotha-
lamic involvement through multiplanar imaging. The MRI ﬁndings
characteristic of CG are an isointense ovoid mass on T1-weighted
MR (63% of cases) and slightly hyperintense T2-weighted images,
with homogeneous enhancement by gadolinium (70%). Most
tumors are solid, but 25% of them display some cystic area within
their periphery. Sagittal images clearly depict the infundibulum
displaced posteriorly, and the largest portion of these ovoidmasses
generally occurs in the superoinferior orientation [10,11].
3.4. Pathological diagnosis
Histopathologically, the tumor consists of clusters and cords of
oval to polygonal epithelioid-shaped cells with eosinophilic cyto-
plasms,whichareembedded inamucinousmatrix.Mitoses are rare
and necrosis is absent. Lymphoplasmacytic inﬁltrates and Russell
bodies are often found in the tumor [9,12].
Immunohistochemically, CG is strongly and diffusely positive
for GFAP and vimentin, and shows focal reactivity to EMA and
cytokeratin in somecases, but littleorno reactivity toS-100protein.
Some authors reported immunoreactivity for CD34, which is
useful for making differential diagnoses between chordoid menin-
gioma, pilocytic astrocytoma, and/or ependymoma [2,9,12].
The diagnosis of CG was supported in our case by both the
well-characterized morphology and immunohistochemistry ﬁnd-
ings. The pathologic examination disclosed cords and clusters of
epithelioid cells within a mucinous matrix (Fig. 3A). No anaplas-
tic features were identiﬁed. Immunohistochemically, tumor cells
were positive for GFAP (Fig. 3B), EMA (Fig. 3C) and focal for CD 34
(Fig. 3D), as well as negative for pan-cytokeratin, protein S-100 and
synaptophysin. The Ki-67 labeling index was 2%. No accumulation
of p53 was observed.
The diagnosis in the current report was challenged by the loca-
tion of the tumor and by secondary alterations related to previous
treatment, which could also be associated with chordoid menin-
gioma, chordoma and metastatic epithelial neoplasms. Given that
necrosis, vascular alterations and hemorrhage are morphologic
features of primary high-grade neoplasms or metastasis, these
diagnoses are ruled out by the fact that we did not observe these
characteristics and that surgery and previous radiotherapy had
therapeutic effects. Moreover, the neoplastic cells showed glial
differentiation and a low proliferative index, as well as a lack of
epithelial or chondro-osseous markers. These ﬁndings ruled out
the diagnoses of meningioma, chordoma and carcinoma.
The histogenesis of CG remains uncertain. Two recent reports
suggested a subcommissural origin based on ultrastructural ﬁnd-
ings. Electron microscopy ﬁndings are also suggestive of glial
origin, especially of ependymal cells known as tanycytes, which
are located in the anterior third ventricle and cover the circumven-
tricular organs in the anatomic vicinity of the third ventricle, the
organum vasculosum of the lamina terminalis and the subfornical
organ [6,10,13].
In all cases of CG reported to date, the anatomic site of origin
can be traced to the lamina terminalis. This origin accounts for a
number of the tumor’s observed properties, including the circum-
scribed gross morphology, the fusiform shape, and certain speciﬁc
endocrine disturbances that are regulated by the organum vascu-
losum [8,12].
The vasculature of these circumventricular organs lacks a blood-
brain barrier,which is associatedwith the typical uniformcontrast-
enhancement observed in neuroimaging studies of CG [10].
3.5. Treatment
There is controversyover themostappropriate treatment forCG.
Most reported caseswere surgically resected (eitherwith complete
or subtotal resection) while others were submitted to stereotactic
biopsy.
The current treatment of choice for CG is surgical resection.
Gross total resection (GTR) is the ideal treatment, although tumor
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size and location often impede radical resection. When this is the
case, the risk of surgical morbidity (often associated with optical
and endocrinological symptoms) cannot be ignored. Low grade,
incompletely resected tumors will continue to grow slowly and
may require later resection.
The few cases that reported using chemotherapy and/or radio-
therapy showed these therapies to be ineffective [2] Gamma knife
radiosurgery (GKRS), indicated2–4months after a partial resection,
has also shown acceptable effectiveness [2,13].
There is enough evidence to support indication of stereotac-
tic radiosurgery after partial resection or biopsy, as patients who
received this treatment had better overall survival rates without
majormorbidity (theymainly experienced optic neuropathy). Nev-
ertheless, total radiation dose and treatment volume remain to be
determined [13].
3.6. Complications
Mortality rates and complications related to the surgical pro-
cedures vary according to surgical technique. GTR has led to
postoperative death in 29% of cases, and a 67% chance of com-
plications among survivors. After partial resection, mortality and
morbidity decreased to 14% and 50%, respectively. In cases where
only biopsy was performed, no deaths or complications were
reported. GTR carries signiﬁcant risk because of the proximity
between the tumor and critical neurovascular structures [13,14].
In 2010, DeSouza et al. [15] reported that death is most likely to
occur in the ﬁrst month postoperatively due mostly to pulmonary
embolism (42%) or cardiovascular causes.
The most commonly-reported complications are: cognitive dis-
orders, pulmonary embolism and hypothalamic dysfunction. There
is also a high incidence of postoperative thromboembolic events,
but the causesbehind theseeventshaveyet tobe identiﬁed [2,5,13].
3.7. Outcome
Clinical outcomes for CG cases reported so far have been poor,
which is partially due to the deep location of the tumor, and also
due to typical tumor features such as solid consistency and adher-
ence to critical neurovascular structures,whichoften render radical
resection difﬁcult or impossible [13–15].
4. Conclusion
CG has distinct features that allow for a deﬁnitive diagnosis.
Efﬁcient treatment depends upon radical surgical resection. Based
on the revieweddata,which showedhighmorbi-mortality rates for
this kind of tumor, we recommend a more conservative treatment
approach.
In cases where local circumstances preclude radical resection,
partial resection with adjuvant radiosurgery should be performed.
To date, no chemotherapeutic regimen has been shown to be effec-
tive for CG.
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